A 47-year-old man with Epstein-Barr virus (EBV)-positive T/NK-cell lymphoproliferative disease (EBV-T/NK-LPD) developed acute-onset weakness. A nerve conduction study showed a conduction block in both the proximal and most distal segments. Although the patient's neuropathy transiently responded to intravenous immunoglobulin, it was progressive for at least 25 days until the start of prednisolone (PSL) administration, after which it remarkably improved. The neuropathy further improved after allogeneic bone marrow transplantation (BMT). The present patient's clinical course is not consistent with that of typical GuillainBarré syndrome. This case suggests that EBV-T/NK-LPD can cause progressive immune-mediated neuropathy as a result of chronic EBV antigen presentation and can be treated with PSL and BMT.
Introduction
Epstein-Barr virus-positive T/NK-cell lymphoproliferative disease (EBV-T/NK-LPD) was originally reported as chronic active EBV infection (CAEBV), a disorder causing recurrent infectious mononucleosis-like symptoms (1) . EBV persistently infects T cells or NK cells in patients with CAEBV as well as hydroa vacciniforme-like lymphoma or hypersensitivity to mosquito bites. EBV-infected cells subsequently expand and produce cytokines, resulting in the development of fatal diseases, such as lymphoma or hemophagocytosis (2, 3) . At present, this condition is termed EBV-T/NK-LPD and is classified as part of the vast spectrum of EBVassociated T-/NK-cell neoplasms (2) . Although resistant to chemotherapy, EBV-infected cells can be effectively eradicated with allogeneic hematopoietic stem cell transplantation (4, 5) .
We herein describe the case of a patient with a CAEBV type of EBV-T/NK-LPD who developed progressive immune-mediated neuropathy. This case was presented as case 17 in our previous analysis of adult-onset CAEBV (6) ; however, the detailed clinical and neurological findings were not included at that time.
Case Report
A 47-year-old Japanese man presented with 10-kg body weight loss, fatigue and fever lasting for 11 months. He had systemic lymphadenopathy with elevated liver enzymes and high EBV antibodies (anti-VCA IgG: 1:1,280, EA-IgG: 1:640). The titer of EBV-DNA in the whole peripheral blood, as measured using a previously reported method (7), was remarkably elevated (Table 1) . We separated the mononuclear cells from the PB with anti-CD4, CD8, CD19 or CD56 antibody-conjugated magnetic beads and examined the EBV-DNA load in each fraction using quantitative RT-PCR. As a result, the EBV-infected cells were found to be CD4-positive. The clonality of the infected cells was confirmed using a Southern blot analysis of the EBV terminal repeat sequence. A pharyngeal lymph node biopsy and blood smear ruled out other lymphomas. The patient was di- To assess motor nerve activity, the ulnar and tibial nerves were stimulated at the wrist/below elbow/above elbow/axilla/Erb point and ankle joint/popliteal joint, respectively. MCVs were measured for the areas between the stimulated points. To assess sensory nerve function, the ulnar nerve was stimulated at the wrist/below elbow/above elbow, and SCVs were measured for the areas between the digit and wrist/wrist and below elbow/below elbow and above elbow. CMAP amplitude, MCVs, SNAP amplitude and SCVs are described in this order.
agnosed with EBV-T/NK-LPD according to the relevant diagnostic criteria (8) .
We subsequently administered chemotherapy, including CP therapy (cyclosporine: 3 mg/kg/day and prednisolone: 1 mg/kg) for 16 days followed by CHOP therapy (cyclophosphamide A: 750 mg/m 2 day 1, doxorubicin: 25 mg/m 2 days 1 and 2, vincristine: 2 mg/m 2 day 1, prednisolone: 50 mg/m 2 days 1-5) and Capizzi therapy (cytarabine: 3 g/m 2 every 12 h ×2, L-asparaginase: 6,000 μ/m 2 ×1, prednisolone: 30 mg/ m 2 days 1-2). Five days after receiving L-asparaginase, the patient reported weakness (day 0). The muscle strength in the limbs was scored diffusely as 4 + according to the Medical Research Council (MRC) score. On day 3, the patient's weakness further progressed, and he could no longer bend his knees; the muscle strength of the distal lower extremities was 0-1 according to the MRC score, and the grip strength was 7.5 kg/6 kg (right/left). Deep tendon reflexes were absent in all four limbs. While the patient's light touch and pain sensation was normal, his vibratory and positional senses were mildly impaired distally. Following the completion of chemotherapy, the EBV-DNA titer in the serum decreased to approximately 1/140 of that observed on admission (Table 1) . However, autoimmune-related antibodies, such as ANA, c-ANCA and p-ANCA, and anti-ganglioside antibodies, such as IgG and IgM for GM1, GM1b, GD1a, GalNAc-GD1a, GQ1b, GD1b, GT1a and LM1, were negative in the serum. A cerebrospinal fluid (CSF) examination showed elevated protein with mild pleocytosis as well as an elevated EBV-DNA titer, as measured according to the method used to assess the peripheral blood (7) ( Table 1) . A PCR examination for HSV1 and 2, VZV, CMV, HHV 6, 7 and 8, BK virus, JC virus and parvovirus B19 was negative in both the serum and CSF. A nerve conduction study (NCS) of the left ulnar nerve showed a partial conduction block between the axilla and Erb's point, with no F-waves ( Figure A) . In addition, the motor nerve conduction velocity (MCV) was found to have mildly decreased, and the compound muscle action potential (CMAP) amplitude also severely decreased, in the left ulnar and tibial nerves (Table 2). Furthermore, the distal latency was prolonged in both the left ulnar and tibial nerves, while the sensory nerve action potential amplitude of the left sural nerve moderately decreased.
We therefore administered intravenous immunoglobulin (IVIG) at a dose of 400 mg/kg per day beginning on day 6 for five days according to the protocol for Guillain-Barré (Table 2) . On day 20, the patient's weakness became exacerbated and returned to the same level as that observed prior to the administration of IVIG. On day 23, we performed a sural nerve biopsy, which showed no infiltrating inflammatory cells or fibrinoid necrosis. Toluidine blue staining revealed thin myelinated fibers; the teased fibers exhibited paranodal retraction with myelin ovoids. In situ hybridization using EBV-encoded small RNA-1 (EBER1) demonstrated no positive signals. These sural nerve biopsy findings suggested the demyelination with secondary axonal degeneration without infiltration of EBV-infected lymphocytes.
Since there were no signs of recovery of the muscle weakness, we started prednisolone (PSL) treatment (1 mg/kg per day) on day 25 in order to interrupt the sustained immune reaction with the EBV-T/NK-LPD cells. Starting the following day (day 26), the patient's weakness began to gradually improve. Three months after the initiation of PSL (day 108), he was able to walk with the assistance of a walking device. In addition, his vibratory and positional senses had mildly recovered in the distal limbs, and NCS showed that the conduction block between the axilla and Erb's point had moderately improved. Furthermore, the CMAP amplitudes had diffusely increased, suggesting that the previous conduction block in the most distal segments was also improving ( Figure C) . Both the MCV and CMAP amplitudes had also improved in the left ulnar nerve (Table 2).
On the other hand, the patient's cell count, protein level and EBV-DNA titer in the CSF remained high three weeks after the start of PSL therapy (day 102) ( Table 1) . The main population of infiltrating cells in the CSF was CD4-positive cells, thus suggesting that they are EBV infected T-cells. In order to eradicate these cells, intrathecal chemotherapy (methotrexate: 15 mg/day and PSL: 10 mg/day, without cytarabine: 40 mg/day) was administered. Although the cell count in the CSF decreased, the protein level and EBV-DNA titer remained high (Table 1) . On day 171, allogeneic bone marrow transplantation (BMT) from an unrelated donor was performed, with non-myeloablative conditioning consisting of fludarabine (25 mg/m 2 ), melphalan (80 mg/m 2 ) and total body irradiation (4 Gy). On day 212, 41 days after BMT, engraftment was confirmed, and the EBV-DNA in both the serum and CSF became undetectable (Table 1) . Subsequently, the dose of PSL was tapered.
Four months after BMT, NCS indicated that the conduction block and CMAP amplitudes had further improved, and the prolonged distal latency in the left ulnar nerve had normalized (Table 2 ). In addition, the fastest F-wave latency was shortened, and the F-waves were more concentrated ( Figure D) . The patient has experienced no episodes of relapse of neuropathy as of six years after BMT. At present, he is able to walk independently without a cane, and his neurological findings are almost normal.
Discussion
The development of EBV infection can precede the Guillain-Barré syndrome in which EBV antigens are thought to trigger an abnormal immune reaction (9, 10) . In the present case, acute-onset muscle weakness and conduction blocks in the proximal and most distal segments, as measured using NCS, were similar to the findings of GuillainBarré syndrome (11) . In particular, some forms of acute motor axonal neuropathy (AMAN) and acute motor and sensory axonal neuropathy (AMSAN): i.e., subtypes of Guillain-Barré syndrome, present with rapidly reversible conduction block and a prolonged distal latency (12) . In these patients, the distal CMAP amplitudes may rapidly increase, and the distal latency, if prolonged, will normalize. The present patient showed similar electrophysiological findings: i.e., the distal CMAP amplitudes increased and the prolonged distal latency normalized after treatment. Therefore, neuropathy associated with EBV-T/NK-LPD may have a pathogenesis similar to that of some forms of AMASAN. Although the current patient's neuropathy transiently responded to IVIG therapy, it remained progressive for at least 25 days until it improved remarkably following PSL administration. Therefore, we considered that the patient's progressive course and response to PSL therapy are not consistent with that of typical Guillain-Barré syndrome (13, 14) .
Takahashi et al. reported the case of a patient who acquired a complicated form of immune-mediated neuropathy during a course of CAEBV (3) . Although the authors diagnosed the patient with Guillain-Barré syndrome, the neuropathy was refractory to multiple cycles of IVIG and persisted for five months until the patient died of hemophagocytosis. While they did not confirm the effects of PSL or BMT, we speculate that their patient had a pathogenesis similar to that observed in our case.
Guillain-Barré syndrome follows a monophasic course, possibly due to the effects of a self-remitting infection (14) . However, the CAEBV type of EBV-T/NK-LPD is associated with chronic EBV infection and continuously presents with EBV antigens, which may trigger a persistent abnormal immune reaction. This hypothetical pathogenesis is compatible with the progressive course noted in the current case and may explain why our patient responded well to PSL, as daily PSL administration continuously suppresses abnormal immune reactions. In this setting, BMT is the ideal treatment for eradicating EBV-infected cells and inhibiting EBV antigen presentation, thereby terminating the persistent abnormal immune reaction. In fact, our patient experienced no episodes of relapse of neuropathy six years after BMT, without PSL therapy. We speculate that the CAEBV type of EBV-T/NK-LPD evokes a persistent abnormal immune reaction via the chronic presence of EBV antigens, thus leading to the development of progressive immune-mediated neuropathy.
Two previous reports have demonstrated infiltration of EBV-infected T cells into various tissues, including the central nervous system, in patients with CAEBV by becoming vasculitic (15, 16) . The authors considered that infiltrated EBV-infected T cells directly cause neurological symptoms. However, this phenomenon was unlikely in our case because the sural nerve biopsy was negative for EBV-infected T cells and the patient's clinical course did not parallel the activity of EBV-T/NK-LPD. In the present case, neuropathy developed five days after the administration of L-asparaginase, which greatly reduced the EBV-DNA titer. Based on this close timing, we speculate that the chemotherapy released a large amount of EBV antigens by destroying numerous lymphocytes, thus triggering the development of immune-mediated neuropathy. This causative relationship should be investigated in a future study in order to establish a safer treatment.
While the administration of systemic chemotherapy reduced the EBV-DNA titer in the serum in the present case, the EBV-DNA titer was higher in the CSF (Table 1 ). This finding suggests that EBV-infected cells can survive in the CSF by using the fluid as a sanctuary, as the CSF is relatively isolated and protected from chemotherapeutic treatment by the blood-brain barrier. Notably, in the present case, intrathecal chemotherapy was partially effective, whereas BMT eradicated EBV from the CSF.
In conclusion, this case suggests that EBV-T/NK-LPD, especially the CAEBV type, can induce progressive immunemediated neuropathy, possibly via chronic EBV antigen presentation, and that this neuropathy can be treated with PSL and BMT.
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